Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Reinvestment Rate
Contineum Therapeutics, Inc. Class A Common Stock cash flow reinvestment rate. Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow Reinvestment Rate of 1.09x as of June 2023, reinvesting $44.49 Million (capex $31.00K plus investments $-44.46 Million) from operating cash flow of $40.67 Million. Explore debt repayment capacity of Contineum Therapeutics, Inc. Class A Com to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Contineum Therapeutics, Inc. Class A Common Stock (2023–2023)
Cash flow reinvestment rate of Contineum Therapeutics, Inc. Class A Common Stock from 2023 to 2023. Historical reinvestment intensity for Contineum Therapeutics, Inc. Class A Common Stock across 1 annual periods. Explore reinvestment intensity of Contineum Therapeutics, Inc. Class A Com to see what proportion of operating cash flow is directed to capital expenditures.
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow Reinvestment Rate by Year (2023–2023)
Contineum Therapeutics, Inc. Class A Common Stock cash flow reinvestment rate by year from 2023 to 2023. Year-by-year capital reinvestment analysis for Contineum Therapeutics, Inc. Class A Common Stock. For the full cash flow conversion analysis, see CTNM operating cash flow.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 3.41x | $65.98 Million | $19.35 Million | $414.00K | — |